Last reviewed · How we verify
Henagliflozin Proline Tablets treatment
Henagliflozin Proline Tablets treatment is a Small molecule drug developed by Bin Lu. It is currently FDA-approved.
At a glance
| Generic name | Henagliflozin Proline Tablets treatment |
|---|---|
| Sponsor | Bin Lu |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effects of Henagliflozin Proline and Metformin XR on Body Composition in Geriatric Patients With Newly Diagnosed T2DM (PHASE4)
- Efficacy and Safety of HRS-1780 Tablets and Henagliflozin Proline Tablets in Patients With Chronic Kidney Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Henagliflozin Proline Tablets treatment CI brief — competitive landscape report
- Henagliflozin Proline Tablets treatment updates RSS · CI watch RSS
- Bin Lu portfolio CI
Frequently asked questions about Henagliflozin Proline Tablets treatment
What is Henagliflozin Proline Tablets treatment?
Henagliflozin Proline Tablets treatment is a Small molecule drug developed by Bin Lu.
Who makes Henagliflozin Proline Tablets treatment?
Henagliflozin Proline Tablets treatment is developed and marketed by Bin Lu (see full Bin Lu pipeline at /company/bin-lu).
What development phase is Henagliflozin Proline Tablets treatment in?
Henagliflozin Proline Tablets treatment is FDA-approved (marketed).